Liptruzet Recall Will Likely Deplete Supply

LIPTRUZET (ezetimibe and atorvastatin) tablets
LIPTRUZET (ezetimibe and atorvastatin) tablets
Merck has announced a voluntary recall of all lots of Liptruzet tablets due to packaging defects.

Merck has announced a voluntary recall of all lots of Liptruzet (ezetimibe/atorvastatin) 10mg/10mg, 10mg/20mg, 10mg/40mg, and 10mg/80mg tablets from all wholesalers in the U.S. and Puerto Rico due to defects in packaging. 

Liptruzet is a combination cholesterol absorption inhibitor and HMG-CoA reductase inhibitor used in primary or mixed hyperlipidemia, and in homozygous familial hypercholesterolemia.

Defective outer laminate foil pouches may allow air and moisture inside the packaging, which could potentially alter the effectiveness or characteristics of Liptruzet. However, the likelihood of the packaging defect affecting product efficacy or being unsafe is remote. 

The recall includes all lots that have been distributed since its launch in May 2013 and is expected to deplete all available supply in the U.S.

The two active ingredients of Liptruzet, ezetimibe and atorvastatin, remain available as separate entities. Liptruzet is not being recalled from pharmacies or patients. Patients may continue taking product that is in their possession as prescribed.

Merck is working to resupply Liptruzet as soon as possible.

For more information call (800) 672-6372 or visit